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patients with low muscle mass: The randoms u m m a r y
Background and aims: The efﬁcacy of nutritional intervention to enhance short- and long-term outcomes
of pulmonary rehabilitation in COPD is still unclear, hence this paper aims to investigate the clinical
outcome and cost-effectiveness of a 12-month nutritional intervention strategy in muscle-wasted COPD
patients.
Methods: Prior to a 4-month pulmonary rehabilitation programme, 81 muscle-wasted COPD patients
(51% males, aged 62.5 ± 0.9 years) with moderate airﬂow obstruction (FEV1 55.1 ± 2.2% predicted) and
impaired exercise capacity (Wmax 63.5 ± 2.4% predicted) were randomized to 3 portions of nutritional
supplementation per day (enriched with leucine, vitamin D and polyunsaturated fatty acids) [NUTRI-
TION] or PLACEBO (phase 1). In the unblinded 8-month maintenance phase (phase 2), both groups
received structured feedback on their physical activity level assessed by accelerometry. NUTRITION
additionally received 1 portion of supplemental nutrition per day and motivational interviewing-based
nutritional counselling. A 3-month follow-up (phase 3) was included.
Results: After 12 months, physical capacity measured by quadriceps muscle strength and cycle endur-
ance time were not different, but physical activity was higher in NUTRITION than in PLACEBO (D1030
steps/day, p ¼ 0.025). Plasma levels of the enriched nutrients (p < 0.001) were higher in NUTRITION than
PLACEBO. Trends towards weight gain in NUTRITION and weight loss in PLACEBO led to a signiﬁcant
between-group difference after 12 months (D1.54 kg, p ¼ 0.041). The HADS anxiety and depression
scores improved in NUTRITION only (D-1.92 points, p ¼ 0.037). Generic quality of life (EQ-5D) was
decreased in PLACEBO but not in NUTRITION (between-group difference after 15 months 0.072 points,
p ¼ 0.009). Overall motivation towards exercising and healthy eating was high and did not change
signiﬁcantly after 12 months; only amotivation towards healthy eating yielded a signiﬁcant between-
group difference (D1.022 points, p ¼ 0.015). The cost per quality-adjusted life-year after 15 months
was EUR 16,750.
Conclusions: Nutritional intervention in muscle-wasted patients with moderate COPD does not enhance
long-term outcome of exercise training on physical capacity but ameliorates plasma levels of thehavioural Regulation in Exercise Questionnaire-2; CET, Cycle endurance time; COPD, Chronic obstructive pulmonary
A, Docosahexaenoic acid; DLCO, Diffusion capacity of the lung for carbon monoxide; EPA, Eicasopentaenoic acid; EQ-
, Forced expiratory volume in 1 s; FVC, Forced vital capacity; FFMI, Fat-free mass index; HADS, Hospital Anxiety and
s ratio; MI, Motivational interviewing; PA, Physical activity; PAL, physical activity level; PR, Pulmonary rehabilitation;
sted life year; QMS, Quadriceps muscle strength; REBS, Regulation of Eating Behaviour Scale; SDT, Self-determination
ical Centre, P. O. Box 5800, 6202 AZ, Maastricht, the Netherlands.
A.M.W.J. Schols).
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patients with low muscle mass: The randomsupplemented nutrients, total body weight, physical activity and generic health status, at an acceptable
increase of costs for patients with high disease burden.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Extra-pulmonary pathology enhances disease burden in pa-
tients with chronic obstructive pulmonary disease (COPD) [1].
Decreased muscle mass is associated with increased prevalence of
osteoporosis, lower muscle strength and exercise performance, and
increased mortality risk [2]. Furthermore, COPD is characterized by
impaired muscle oxidative metabolism, which cannot simply be
explained by disuse alone [3,4] and may predominate in patients
with low muscle mass [5].
Exercise training is a cornerstone of pulmonary rehabilitation
(PR) [6], and improves lower limb muscle strength, exercise per-
formance, and in some studies also daily physical activity level [7,8].
Protein and speciﬁc nutrient supplementation could potentiate the
effects of PR or represent an alternative to exercise training in
severely deconditioned patients. In contrast to other nutrients
including creatine and nitrate [9], to date only polyunsaturated
fatty acids (PUFA) [10] and vitamin D [11] have been effective as
single-nutrient add-on treatment in COPD by enhancing inspira-
tory muscle strength [11] and maximal oxygen uptake [10,11]
during PR which could be via immune modulation and/or boost-
ing oxidative metabolism. Multimodal nutritional interventions are
interesting to explore because the regulation of muscle mass and
metabolism is controlled by multiple tightly intertwined pathways
[12]. In the NUTRAIN trial [13], we developed a multimodal step-
wise nutritional intervention approach including high-quality
protein enriched with leucine, vitamin D, and omega-3 PUFA,
based on evidence regarding the mode of action of these nutrients
on skeletal muscle maintenance, combined with reported de-
ﬁciencies in COPD. The nutritional supplementationwas supported
by nutritional counselling. This approach was investigated in COPD
patients with low muscle mass as a susceptible group for acceler-
ated functional decline [14]. The results of the ﬁrst phase, which
took place during PR, have been reported earlier [13]. During this
phase nutritional supplementation improved nutritional status but
did not enhance lower limbmuscle strength or muscle mass regain.
A remarkable between-group difference was shown in physical
activity level, largely due to a decline in the PLACEBO group only,
whereas the NUTRITION group remained stable, indicating that this
nutritional strategy might be effective to attenuate the decline in
physical activity typically observed in patients with COPD [15].
Exercise-induced muscle fatigue is a commonly reported symptom
in COPD [16], and nutritional modulation thereof or nutritional
effects beyond the muscle (i.e., the brain or cardiovascular system)
[17,18] might explain this observation. Accordingly, Calder et al. [19]
showed in a 3-month randomized controlled trial that supple-
mentation with high-quality protein enriched with omega-3 PUFA
and vitamin D, reduced walking exercise-induced fatigue
(measured using the Borg scale) in COPD patients with low muscle
mass.
We hypothesized that improved nutritional status and positive
effects on daily physical activity level might also enhance the long-
term efﬁcacy of the intervention with quadriceps muscle strength
(QMS) as primary outcome. The current paper aims to investigate
the clinical outcome of the overall nutritional management strat-
egy of the NUTRAIN trial, including phase 1, the 8-month, Clinical outcome and cost-e
ized controlled NUTRAIN trimaintenance phase after completion of PR (phase 2) and the 3-
month follow-up (phase 3). Furthermore, the cost-effectiveness of
the intervention after 15 months is explored.2. Methods
2.1. Study design
The trial was integrated in the outpatient PR programme of 7
hospitals in the Netherlands (Sint Anna hospital in Geldrop, Max-
ima Medical Centre in Veldhoven (until March 2013), Laurentius
hospital in Roermond, Sint Jans Gasthuis hospital in Weert, Elker-
liek hospital in Helmond, Maastricht University Medical Centre and
Catharina hospital in Eindhoven), supervised by CIRO, a centre of
expertise for patients with chronic organ failure in Horn. Partici-
pants were recruited during the assessment period at CIRO when
eligible for outpatient PR at one of the hospitals. Patients with se-
vere COPD referred for inpatient PR at CIRO were not included.
Every participant underwent an interviewwith a chest physician at
admission; the study physician checked eligibility of potential
participants during this visit and asked participants whether they
could be contacted by the researcher. The study was registered at
clinicaltrials.gov (NCT01344135) and the Medical Ethics Committee
of Maastricht University Medical Centre granted ethical approval
(NL34927068.10/MEC 11-3-004). All participants provided written
informed consent.
The intervention was divided into a 4-month nutritional inter-
vention (phase 1) and an 8-month maintenance phase (phase 2). In
short, in the double-blind controlled intervention phase 1, 81 pa-
tients were randomized to the PLACEBO (n ¼ 39) or NUTRITION
group (n ¼ 42). Both groups underwent a supervised centre-based
exercise training programme and were advised to consume 3 oral
nutritional supplements daily. The NUTRITION product provided
protein, carbohydrates, fat and micronutrients, and was enriched
with leucine, omega-3 PUFA, and vitamin D (Nutricia NV, Zoeter-
meer, The Netherlands). The PLACEBO product did not comprise the
active components, but consisted of a ﬂavoured non-caloric clou-
diﬁed aqueous solution. For details see Van de Bool et al. [13].
In the open-label maintenance phase (phase 2), both groups
received feedback on their physical activity behaviour twice,
based on accelerometry. This was done in order to offer both
groups a follow-up intervention aimed at maintaining long-term
efﬁcacy of the exercise training. In addition, participants in
NUTRITION were advised to take 1 oral nutritional supplement
per day and received four nutritional counselling sessions. These
were provided by trained nurses, and aimed to optimize partic-
ipants’ dietary habits and maximize adherence to a healthy diet
and the supplement regime. The counselling was based on self-
determination theory (SDT) [20], which assumes that autono-
mous forms of motivation are essential to achieve lasting
behavioural change, and it was operationalized through moti-
vational interviewing (MI) [21]. After the 8-month maintenance
phase, participants were followed up for three months, without
any intervention taking place in either group (phase 3). Figure 1
depicts a ﬂowchart of the study; Fig. 2 outlines the study design.ffectiveness of a 1-year nutritional intervention programme in COPD
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Fig. 1. Consort ﬂow chart.
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Patients with COPD (post-bronchodilator FEV1 / FVC < 0.7)
referred for outpatient PR between September 2011 and April 2014
were eligible for participation if they had lowmuscle mass, deﬁned
as a fat-free mass index (FFMI) below the sex- and age-speciﬁc 25th
percentile FFMI-values [22]. Exclusion criteria were age under 18
years old, allergy or intolerance to components of the study prod-
uct, investigator's uncertainty about patient's willingness or ability
to comply with the protocol requirements, inability to stop current
supplement use, participation in any other study involving inves-
tigational or marketed products concomitantly or less than two
weeks prior to entry into the study, pregnancy, or life-threatening
diseases.
2.3. Outcomes
Quadriceps muscle strength (QMS), assessed by dynamometry
(System 4 Pro; BiodexMedical Systems Inc., New York, USA), served
as the primary outcome of this study. QMS, body composition
measured by dual energy x-ray absorptiometry (DEXA) (Lunar
Prodigy system; GEHealthcare, Madison,WI, USA), cycle endurance
time (CET) on a cycle ergometer (Carefusion, Houten, The
Netherlands) (determined during the constant work rate cycling
endurance test at 75% of the peak workload), and fasting plasma
levels of vitamin D, eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA) and leucine were measured at baseline (before entering
PR), and after phase 1 and 2. Habitual dietary intake of the last
monthwas assessed at these time points by trained dieticians using
a validated cross-check dietary history method and calculated us-
ing the Dutch Food Composition Database. Mental and physical
health status, assessed by the Hospital Anxiety and DepressionPlease cite this article as: van Beers M et al., Clinical outcome and cost-e
patients with low muscle mass: The randomized controlled NUTRAIN triScale (HADS) [23], EuroQoL Five-Dimensions Questionnaire (EQ-
5D-3L) [24], St George's Respiratory Questionnaire (SGRQ) [25], and
PAL (physical activity level) as assessed by daily steps by a tri-axial
GT3X Actigraph accelerometer (Health One Technology, Fort Wal-
ton Beach, FL, USA) were measured at baseline and after phase 1, 2
and 3. Post-bronchodilator forced expiratory volume in 1 second
(FEV1) and forced vital capacity (FVC) were assessed by stand-
ardised equipment (Masterlab®; Jaeger, Wurzburg, Germany), in
accordance with the latest GOLD guidelines [26]. The Dutch value
set was used to transform EQ-5D scores into utilities [27]. Adopting
such a wide range of outcome measures is in line with the rec-
ommendations of the joint ATS/ERS task force on outcome mea-
sures in COPD to use a multi-outcome approach [28].
Participants' motivational proﬁles towards exercising and
healthy eating were assessed using the Behavioural Regulation in
Exercise Questionnaire-2 (BREQ-2) [29] and the Regulation of
Eating Behaviour Scale (REBS) [30], respectively, at baseline and
after phase 1, 2 and 3. These questionnaires are based on SDT and
they provide six subscale scores (see [20] for details). Answers were
given on a 5-point Likert scale in both questionnaires. Scores on the
BREQ subscales range from 1 (lowest possible motivation) to 5
(highest possible motivation). Scores on the REBS range from
0 (lowest possible motivation) to 10 (highest possible motivation).
Internal consistency measured by Cronbach's awas adequate for all
scales, except for identiﬁed regulation towards exercising
(a ¼ 0.319 after phase 2). Consequently, this scale was excluded
from subsequent analyses.
2.4. Costs
Total costs (not only related to COPD) were calculated from a
healthcare and a societal perspective. The healthcare perspectiveffectiveness of a 1-year nutritional intervention programme in COPD
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Fig. 2. Study design of the NUTRAIN trial.
M. van Beers et al. / Clinical Nutrition xxx (xxxx) xxx4included all costs covered by the healthcare budget. The societal
perspective additionally included travel costs and costs of pro-
ductivity loss due to absence from paid work (absenteeism).
Healthcare utilization, travel distance, and absenteeism were
assessed in a resource use questionnaire after phase 1, 2 and 3.
The intervention costs included the reported number of super-
vised exercise training sessions and their duration, the number of
nutritional supplements used, the number of educational coun-
selling sessions and their duration, the number of consultations for
physical activity level feedback, the number of nutritional coun-
selling sessions, and the travel distance to health care providers.
Standard unit costs were determined using Dutch guideline
prices [31] and inﬂated to 2015 values using the general consumer
price index [32]. The costs of medication were obtained from the
Drug Information System of the Dutch National Health Care Insti-
tute and included value added tax and pharmacist dispensing fees
[33]. The productivity costs were estimated using the Friction Cost
Approach, which assumes that productivity loss occurs as long as a
sick employee is not replaced (the friction period) [34]. We used a
friction period of 85 days. The unit costs are shown in
Supplementary Tables 1 and 2.2.5. Statistical analyses
Statistical analyses were performed using Stata, in accordance
with the intention-to-treat principle.
Plasma levels of the supplemented nutrients, body composition,
motivational proﬁle and physical function were analysed using a
linear repeated measurement model with correlated error terms
and unstructured covariance matrix. The model included treat-
ment, time (i.e., the measurements at 4 and 12 months) and
treatment by time interactions. Data from patients who dis-
continued the trial prematurely were included in the analyses up to
the point of drop-out.
Costs were also analysed in a linear repeated measures model
with correlated error terms and unstructured covariance matrix.
The dependent variable was total costs in a certain phase, and the
explanatory variables were time (4, 12, and 15 months) and the
interaction of treatment and time. The results were used to
predict the mean costs per treatment group for each phase. Total
costs were calculated as the sum of the predicted costs of the
rehabilitation phase, maintenance phase, and follow-up phase.Please cite this article as: van Beers M et al., Clinical outcome and cost-e
patients with low muscle mass: The randomized controlled NUTRAIN triTo assess differences in health outcomes between the two
treatment groups, we also used linear repeated measurement
models with correlated errors and unstructured covariance matrix.
Explanatory variables were time (4, 12 [and, if applicable, 15]
months) and the interaction of treatment and time. We calculated
the number of quality-adjusted life-years (QALYs) for each patient
as the area under the predicted utility curve, using linear interpo-
lation between two measurements.
The costs per gained QALY were calculated as the difference in
total costs between the two groups divided by the difference in
QALYs. Uncertainty around this cost-effectiveness ratio was esti-
mated by performing 5000 bootstrap replications.
2.6. Power calculation
The power calculation was based on the INTERCOM study
assuming a 10% between-group difference in peak torque assuming
maintenance of skeletal muscle strength in NUTRITION during
follow-up and a standard deviation of 5 Nm in peak torque.
Allowing for 25% drop-out yielded a subgroup size of n¼ 60. Patient
inclusion was prematurely discontinued because the test product
could not be produced within the appropriate quality speciﬁcations
due to discontinuation of the supply of one of the ingredients, but
the sample sizewas justiﬁable based on other RCTs published in the
meantime [13].
3. Results
3.1. Patients
Baseline characteristics did not differ between the groups,
except for a higher peak workload in NUTRITION. The study pop-
ulation consisted of 51% males, aged 62.5 ± 0.9 years, and was
characterized by low diffusion capacity (DLCO 49.4 ± 1.7%), mod-
erate airﬂow limitation (FEV1 55.1 ± 2.2% predicted), normal to low
BMI (22.7 ± 0.3 kg/m2), impaired exercise capacity (Wmax
63.5 ± 2.4% predicted), and low FFMI (15.8 ± 1.6 kg/m2) (see
Table 1).
3.2. Physical functioning
No between-group difference was observed in improved phys-
ical capacity (QMS and CET) (see Table 2). When QMS wasffectiveness of a 1-year nutritional intervention programme in COPD
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Table 1
Baseline characteristics.
NUTRITION PLACEBO
Mean ± SE Mean ± SE
General
Gender (% male) 42.9% 59.0%
Age (years) 62.8 ± 1.3 62.2 ± 1.3
Current smokers (%) 19.0% 31.6%
Low SES (no or only primary education) (%) 5.6% 13.3%
Employed (%) 33.3% 19.4%
Number of exacerbations in the last year 1.1 ± 0.2 1.4 ± 0.3
Lung function
FEV1 (% predicted) 57.0 ± 3.3 53.0 ± 2.8
FVC (% predicted) 102.8 ± 2.9 100.6 ± 2.7
FEV1/FVC (%) 44.4 ± 2.0 41.6 ± 1.8
FRC (% predicted) 139.1 ± 4.3 146.7 ± 5.9
Residual volume (% predicted) 143.4 ± 6.3 153.1 ± 8.5
DLCO (% predicted) 51.4 ± 2.2 47.1 ± 2.5
Physical function
QMS (Nm) 121.5 ± 6.4 118.0 ± 6.6
CET (s) 319.0 ± 35.2 231.5 ± 12.0
Peak workload (Wmax) 84.6 ± 5.2 72.5 ± 3.8
Peak workload (% predicted) 69.5 ± 3.3** 57.0 ± 3.4
PAL (steps/day) 4716.7 ± 327.2 4516.6 ± 379.3
Dietary intake
Energy (kcal) 2426.0 ± 168.0 2442.8 ± 174.2
Protein (g) 91.1 ± 5.5 89.9 ± 5.5
Carbohydrates (g) 263.1 ± 19.9 266.8 ± 17.5
Fat (g) 103.1 ± 9.8 105.4 ± 12.3
PUFA (g) 20.2 ± 2.0 21.5 ± 2.7
Cholesterol (mg) 251.5 ± 25.2 239.1 ± 25.2
Dietary ﬁber (g) 21.9 ± 1.3 21.7 ± 1.6
Calcium (mg) 1083.5 ± 96.1 977.3 ± 67.5
Vitamin A (mg) 1241.4 ± 96.5 1192.5 ± 145.8
Vitamin C (mg) 84.1 ± 6.1 85.9 ± 6.9
Vitamin D (mg) 5.3 ± 0.4 5.1 ± 0.6
Vitamin E (mg) 14.6 ± 1.3 13.9 ± 1.2
Supplemented plasma nutrient levels
Leucine (mmol/l) 147.7 ± 3.6 153.5 ± 3.5
Vitamin D (nmol/l) 54.0 ± 4.5 45.3 ± 3.1
EPA (mg/l) 1.1 ± 0.1 1.2 ± 0.1
DHA (mg/l) 2.9 ± 0.2 3.2 ± 0.2
Body composition
Total weight (kg) 64.3 ± 1.6 65.0 ± 1.7
BMC (g) 2331.3 ± 73.0 2414.7 ± 82.3
ASM (kg) 17.4 ± 0.6 18.4 ± 0.6
Fat mass (kg) 20.0 ± 1.0 19.0 ± 1.3
Lean mass (kg) 42.0 ± 1.3 43.6 ± 1.2
BMI (kg/m2) 22.9 ± 0.4 22.6 ± 0.5
FFMI (kg/m2) 15.7 ± 0.3 15.9 ± 0.2
Patient-reported outcomes
EQ-5D 0.8 ± 0.0 0.8 ± 0.0
SGRQ 49.9 ± 2.4 50.1 ± 2.6
HADS Total 10.9 ± 1.2 10.2 ± 1.1
SES: socio-economic status; FEV1: forced expiratory volume in 1 second; FVC: forced
vital capacity; FRC: functional residual capacity; DLCO: diffusion capacity of the lung
for carbon monoxide; QMS: quadriceps muscle strength; CET: cycle endurance
time; PAL: physical activity level; PUFA: polyunsaturated fatty acids; EPA: eicosa-
pentaenoic acid; DHA: docosahexaenoic acid; BMC: bone mineral content; ASM:
appendicular skeletal muscle mass; BMI: body mass index; FFMI: fat-free mass in-
dex; EQ-5D: EuroQoL 5-dimensions questionnaire; SGRQ: St George's Respiratory
Questionnaire; HADS: Hospital Anxiety and Depression Scale. **p < 0.01.
M. van Beers et al. / Clinical Nutrition xxx (xxxx) xxx 5normalized for appendicular lean mass or fat-free mass, the
between-group difference was not signiﬁcant either (data not
shown). Physical activity level was signiﬁcantly lower compared to
baseline in PLACEBO whereas it remained stable in NUTRITION.
This led to a signiﬁcant between-group difference on number of
steps per day (p¼ 0.025) (see Fig. 3). Activity intensity did not differ
signiﬁcantly over time or between the groups: in both groups
across all time points, patients spent around 70% in sedentary
physical activity (PA), 23% in lifestyle PA, 6% in light PA and 1% in
moderate-to-vigorous PA.Please cite this article as: van Beers M et al., Clinical outcome and cost-e
patients with low muscle mass: The randomized controlled NUTRAIN triThe change in physical activity level from baseline to T12
correlated signiﬁcantly with the change in appendicular skeletal
muscle mass index (ASMI) (r¼ 0.371, p¼ 0.022) but not that in total
body weight (r ¼ 0.088, n.s.) in the entire study population.
3.3. Dietary intake and plasma nutrient status
Overall dietary habits represented a typical Western diet and no
signiﬁcant within- or between-group changes were identiﬁed
throughout the trial on any macronutrient or micronutrient, except
for cholesterol intake (see Supplementary Table 1). Cholesterol
intake was signiﬁcantly higher in PLACEBO after 12 months
compared to baseline (p ¼ 0.001), leading to a signiﬁcant between-
group difference (p ¼ 0.003). At baseline, 31.2% of participants had
vitamin D insufﬁciency, whereas 57.5% had vitamin D deﬁciency.
Plasma vitamin D, EPA and DHA levels were signiﬁcantly
increased compared to baseline in NUTRITION. EPA levels were
signiﬁcantly decreased compared to baseline in PLACEBO. Leucine,
vitamin D, EPA and DHA levels signiﬁcantly differed between
groups (see Table 2).
3.4. Body composition
Total body weight, muscle mass and fat mass tended to decrease
within PLACEBO and tended to increase within NUTRITION from
baseline to the end of phase 2. This resulted in a signiﬁcant
between-group difference in total body weight change, in favour of
NUTRITION (D1.54 ± 0.76 kg, p ¼ 0.041) (see Table 2 and Fig. 4).
3.5. Patient-reported outcomes
Total HADS score signiﬁcantly improved in NUTRITION
(p ¼ 0.037). In PLACEBO, the EQ-5D score decreased signiﬁcantly
(p ¼ 0.009) (see Table 2). The SGRQ did not differ signiﬁcantly
within or between groups. After phase 3, EQ-5D utility was still
signiﬁcantly decreased compared to baseline in PLACEBO
(p ¼ 0.011), whereas the between-group difference was also sig-
niﬁcant in favour of NUTRITION, p ¼ 0.034) (see Table 3).
Interestingly, the change in EQ-5D scores from baseline to T12
correlated signiﬁcantly with the change in total body weight
(r ¼ 0.406, p ¼ 0.008) and ASMI (r ¼ 0.456, p ¼ 0.003) in the entire
study population.
3.6. Motivational proﬁle
Motivation towards both exercising and healthy eating was
already high before the counselling sessions started. The mean
scores for intrinsic and identiﬁed motivation towards exercising
before the counselling started were 4.14 and 4.03 out of 5,
respectively. These ﬁgures were 7.69 and 8.42 out of 10 for intrinsic
and identiﬁed motivation towards healthy eating. In NUTRITION,
amotivation towards exercising decreased (p ¼ 0.015), while in
PLACEBO, identiﬁed motivation towards healthy eating decreased
(p ¼ 0.019). Only amotivation towards healthy eating differed
signiﬁcantly between groups (p ¼ 0.015) (see Table 4).
3.7. Intervention costs
Intervention costs are presented in Supplementary Table 1. From
a healthcare perspective, the mean intervention costs of the total
intervention were EUR 2233 per patient in NUTRITION and EUR
1372 in PLACEBO. From a societal perspective, these costs were EUR
2265 and EUR 1404, respectively. The between-group difference is
mainly due to the costs of nutritional supplements. Supervisedffectiveness of a 1-year nutritional intervention programme in COPD
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Table 2
Within- and between-group differences in plasma nutrient status, physical function, body composition, and patient-reported outcomes, after 12 months.
Measure Within-group Between-group
NUTRITION PLACEBO
adj. M (SE) Z adj. M (SE) Z adj. M (SE) Z
Physical function
QMS (Nm) 10.35 (3.51) 2.95** 10.05 (3.46) 2.90** 0.30 (4.92) 0.06
CET (s) 107.1 (62.9) 1.70* 200.3 (64.5) 3.11** 93.2 (89.8) 1.04
PAL (steps/day) 358.8 (339.9) 1.06 671.3 (330.3) 2.03* 1030.1 (459.8) 2.24*
Supplemented plasma nutrient levels
Leucine (mmol/l) 10.41 (5.57) 1.87 6.08 (5.80) 1.05 16.49 (8.01) 2.06*
Vitamin D (nmol/l) 15.10 (2.69) 5.61*** 1.25 (2.77) 0.45 13.85 (3.84) 3.60***
EPA (mg/l) 5.42 (1.66) 3.27** 3.34 (1.64) 2.04* 8.76 (1.95) 4.49***
DHA (mg/l) 7.26 (2.69) 2.70** 4.69 (2.67) 1.76 11.97 (3.47) 3.45**
Body composition
Total weight (kg) 0.64 (0.53) 1.21 0.90 (0.54) 1.67 1.54 (0.76) 2.04*
BMC (g) 9.96 (13.81) 0.72 22.21 (14.12) 1.57 12.26 (19.73) 0.62
ASM (kg) 0.17 (0.21) 0.83 0.22 (0.21) 1.02 0.39 (0.29) 1.32
Fat mass (kg) 0.86 (0.50) 1.71 0.47 (0.51) 0.91 1.33 (0.72) 1.86
Patient-reported outcomes
EQ-5D 0.003 (0.03) 0.10 0.07 (0.03) 2.63** 0.07 (0.04) 1.86
SGRQ 1.43 (1.89) 0.75 0.71 (1.97) 0.04 2.14 (2.73) 0.78
HADS Total 1.92 (0.92) 2.09* 1.50 (0.97) 1.54 0.42 (1.30) 0.32
Values shown as changes from baseline. QMS: quadriceps muscle strength; Nm: Newtonmeter; CET: cycle endurance time; PAL: physical activity level; EPA: eicosapentaenoic
acid; DHA: docosahexaenoic acid; BMC: bone mineral content; ASM: appendicular skeletal muscle mass; EQ-5D: EuroQoL 5-dimensions questionnaire; SGRQ: St George's
Respiratory Questionnaire; HADS: Hospital Anxiety and Depression Scale. *p < 0.05 **p < 0.01 ***p < 0.001.
M. van Beers et al. / Clinical Nutrition xxx (xxxx) xxx6exercise training was the main driver of the intervention costs in
both groups.
3.8. Total costs and cost-effectiveness
Table 5 shows the cost-effectiveness analysis after phase 2 and
3. The differences in various categories of healthcare utilization and
costs over 12 and 15 months are presented in Supplementary
Tables 2 and 3. After phase 2, the costs in NUTRITION were esti-
mated to be EUR 1529 (certainty 87%) higher than in PLACEBO from
the healthcare perspective and EUR 2829 (certainty 98%) higher
from the societal perspective. After phase 3, costs in NUTRITION
were EUR 670 (certainty 64%) higher from the healthcare
perspective and EUR 2401 (certainty 92%) higher from the societal
perspective.Fig. 3. Development of physical activity level as change from baseline. # within-group
p < 0.05 (compared to baseline); *between-group p < 0.05.
Please cite this article as: van Beers M et al., Clinical outcome and cost-e
patients with low muscle mass: The randomized controlled NUTRAIN triBoth from a healthcare and societal perspective, the point-
estimates of costs pointed towards higher costs in NUTRITION
and a higher physical activity level in NUTRITION after phase 2, and
a higher number of QALYs in NUTRITION after phase 3. The prob-
ability that the nutritional intervention was cost-effective at a
willingness-to-pay of EUR 20,000 and EUR 80,000 per QALY was
27% and 59% (after phase 2), and 55% and 82% (after phase 3) (data
not shown).4. Discussion
This paper investigated the clinical beneﬁts and cost-efﬁcacy of
a 12-month multimodal, stepwise nutritional interventionFig. 4. Change in total body weight from baseline to T12. *between-group p < 0.05.
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Table 3
Within- and between-group differences in physical activity level and patient-reported outcomes, after 15 months.
Measure Within-group Between-group
NUTRITION PLACEBO
adj. M (SE) Z adj. M (SE) Z adj. M (SE) Z
PAL (steps/day) 38.1 (355.5) 0.11 834.2 (362.8) 2.30* 796.1 (496.9) 1.60
EQ-5D 0.012 (0.02) 0.49 0.060 (0.02) 2.53* 0.072 (0.03) 2.12*
SGRQ 0.16 (2.11) 0.08 2.72 (2.19) 1.24 2.56 (3.00) 0.86
HADS Total 0.85 (0.97) 0.87 1.74 (0.98) 1.78 0.89 (1.38) 0.65
Values shown as changes from baseline. PAL: physical activity level; EQ-5D: EuroQoL 5-dimensions questionnaire; SGRQ: St George's Respiratory Questionnaire; HADS:
Hospital Anxiety and Depression Scale. *p < 0.05.
Table 4
Within- and between-group differences in motivational proﬁle, after 12 months.
Measure Within-group Between-group
NUTRITION PLACEBO
adj. M (SE) Z adj. M (SE) Z adj. M (SE) Z
Exercise
Intrinsic 0.069 (0.11) 0.60 0.011 (0.12) 0.09 0.058 (0.16) 0.36
Introjected 0.183 (0.16) 1.12 0.212 (0.17) 1.25 0.396 (0.23) 1.72
External 0.006 (0.10) 0.06 0.006 (0.10) 0.06 0.012 (0.13) 0.09
Amotivation 0.232 (0.10) 2.43* 0.011 (0.10) 0.17 0.215 (0.13) 1.71
Healthy eating
Intrinsic 0.094 (0.26) 0.36 0.060 (0.27) 0.22 0.154 (0.37) 0.42
Integrated 0.040 (0.29) 0.14 0.230 (0.31) 0.76 0.271 (0.40) 0.67
Identiﬁed 0.028 (0.24) 0.12 0.577 (0.24) 2.35* 0.549 (0.34) 1.60
Introjected 0.437 (0.29) 1.50 0.644 (0.30) 0.21 0.373 (0.41) 0.91
External 0.297 (0.38) 0.78 0.122 (0.39) 0.31 0.175 (0.53) 0.33
Amotivation 0.429 (0.30) 1.44 0.593 (0.31) 1.92 1.022 (0.42) 2.43*
Values shown as change from baseline. *p < 0.05.
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Physical capacity, as primary outcome, was improved in both
groups after 12 months, but NUTRITION took 1030 additional
steps per day compared to PLACEBO. This difference exceeds the
minimal important difference to reduce risk of hospital admission
[35], and it cannot be explained by greater energy substrate
availability, as total macronutrient intake was not signiﬁcantlyTable 5
Cost-effectiveness and cost-utility: 12 and 15 month time horizon.
12 month time horizon NUTR
Costs (euros)
Healthcare perspective (HCP) 8094
Societal perspective (SP) 9404
Effects
QALYs 0.66
PAL (steps/day) 4960
Percentage of patients with þ4 units improvement in SGRQ 0.36
ICER (euros) HCP
Costs/QALY gained 61,16
Costs/1000 additional steps 1499
Cost/additional patient with þ4 units improvement in SGRQ domi
15 month time horizon NUT
Costs (euros)
Healthcare perspective (HCP) 954
Societal perspective (SP) 11,3
Effects
QALYs 0.86
PAL (steps/day) 457
Percentage of patients with þ4 units improvement in SGRQ 0.35
ICER (euros) HCP
Costs/QALY gained 16,7
Costs/1000 additional steps 823
Cost/additional patient with þ4 units improvement in SGRQ 558
*p < 0.05. UI: uncertainty interval; HCP: healthcare perspective; SP: societal perspective
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patients with low muscle mass: The randomized controlled NUTRAIN tridifferent between the groups at T12 (data not shown). This in-
dicates that nutrient-speciﬁc mechanisms could explain the
dissociation between changes in QMS and physical activity via
various synergistic pathways including immune modulation
(PUFA, vitamin D) [36,37], enhancing muscle oxidative meta-
bolism (PUFA) [38] and modifying muscle maintenance regulation
(PUFA, leucine) [39,40].ITION PLACEBO Difference (95% UI)
6565 1529 (1007 to 4343)
6575 2829 (100 to 5802)
0.64 0.025 (0.02 to 0.07)
3940 1020 (17 to 1990)
0.43 0.07 (0.38 to 0.22)
SP
0 113,160
2774
nated dominated
RITION PLACEBO Difference (95% UI)
8 8878 670 (2468 to 4001)
24 8923 2401 (854 to 5824)
0.82 0.04 (0.01 to 0.10)
6 3780 814 (335 to 1838)
0.23 0.12 (0.16 to 0.39)
SP
50 60,025
2950
3 20,008
; QALY: quality-adjusted life year; SGRQ: St George's Respiratory Questionnaire.
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were indeed signiﬁcantly higher in NUTRITION compared to both
baseline and PLACEBO, indicating that the phased intervention
strategy was feasible and overall compliance was good.
Trends towards weight gain in NUTRITION and weight loss in
PLACEBO after 12 months led to a signiﬁcant between-group dif-
ference in total body weight. A tendency to lose weight in PLACEBO
was also found after 12 months in a trial focussing on protein-
calorie supplementation by Weekes et al. [41]. Changes in muscle
and fat mass parallelled total weight change but were not signiﬁ-
cant, possibly due to lack of power. Remarkably, in contrast to
weight change, the subtle change in muscle mass correlated
signiﬁcantly with the change in PA.
Previous studies in weight-losing and muscle-wasted patients
with advanced COPD showed positive short-term (1e4 months)
effects of protein-calorie supplementation as adjunct to exercise
training on physical capacity and muscle mass [42e44], but limited
evidence is available in less advanced airﬂow obstruction. The
INTERCOM trial, which investigated a combined nutritional and
exercise intervention in the subgroup of patients with low muscle
mass and reduced cycle exercise capacity, also showed positive
effects onmusclemass and physical capacity in less advanced COPD
patients with low muscle mass [14]. However, it could not disen-
tangle the relative contributions of the exercise and nutritional
interventions to physical performance, because the muscle-wasted
control group only received usual care. In the 20-month mainte-
nance phase of the INTERCOM trial, physical capacity remained
improved in the subgroup of treated muscle-wasted patients, but
6-min walking distance declined below baseline in those receiving
usual care [14]. Whereas the nutritional intervention strategy had
no short- or long-term added value on physical capacity in the
current trial [13], there were sustained signiﬁcant positive effects
on body weight, plasma nutrient levels and physical activity and a
trend towards improved mental health, which could explain the
difference in generic health status after follow-up.
Both EQ-5D and physical activity levels remained stable in
NUTRITION and declined in PLACEBO after 12 and 15months. These
parallel changes couldmean that generic health status is inﬂuenced
by daily physical activity level via modulation of physiological and/
or mental health.
A qualitative study in a random sample of 22 NUTRAIN partic-
ipants after phase 2 identiﬁed perceived competence and autono-
mous motivation as determinants of a physically active lifestyle
[45]. The limited between-group motivational differences could
be partly explained by high levels of both intrinsic and extrinsic
motivation and low levels of amotivation already apparent before
counselling. Admission to PR already requires being motivated and
participating in an extensive study such as this one even more so.
Even so, slight changes in motivational proﬁle may indicate some
effect of the nutritional counselling.
The incremental cost-effectiveness ratio (ICER) of EUR 61,160
after phase 2 decreased to EUR 16,750 after phase 3, because of a
higher gain in QALYs and lower difference in costs after phase 3.
Whether an intervention is cost-effective or not depends on the
threshold value of the willingness-to-pay for a QALY. In the
Netherlands this threshold depends on disease burden (deﬁned as
proportional shortfall) [46]. A higher threshold applies for condi-
tions with a higher disease burden. There are three categories,
deﬁning a low burden (proportional shortfall of 0.1e0.4 QALYs),
medium (0.41e0.7) and high burden of disease (0.71e1), corre-
sponding to thresholds of EUR 20,000, EUR 50,000, and EUR 80,000
per QALY, respectively [47]. Hence, an ICER below EUR 20,000 (after
phase 3) is generally considered to be cost-effective. With an ICER
of around EUR 60,000 after phase 2, the current nutritional inter-
vention would be cost-effective for COPD patients with a diseasePlease cite this article as: van Beers M et al., Clinical outcome and cost-e
patients with low muscle mass: The randomized controlled NUTRAIN triburden of at least 0.7 QALYs. However, this estimation is associated
with high uncertainty illustrated by a small proportion of bootstrap
replications below a threshold value of EUR 80,000 after phase 2.
A weakness of the current study includes the unblinding after
PR, which was done because it was considered unethical to
continue placebo supplementation during the maintenance phase.
Secondly, as already mentioned, the current study included quite a
small number of patients, in line with many other comparable
studies. Generalizability of the study is limited by the fact that only
patients referred for PR were included. Thirdly, not achieving the
sample size speciﬁed beforehand could limit our ability to detect
signiﬁcant results. Finally, the counselling sessions were given by
nurses who lacked detailed knowledge on the domains to be
improved. More detailed and tailored advice could improve
adherence to a healthy lifestyle and increase health gains.
5. Conclusion
A stepwise multimodal nutritional intervention strategy, con-
sisting of targeted nutritional supplementation and nutritional
counselling, in muscle-wasted patients with moderate COPD does
not enhance long-term outcome of exercise training on physical
capacity but ameliorates plasma levels of the supplemented nu-
trients, body weight, physical activity and generic health status.
This intervention increases total health care costs to a degree that
might be considered acceptable for patients with a high disease
burden.
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